Namaste Technologies (CSE:N; OTCMKTS:NXTTF) announced a deal with PharmaCann to invest and obtain a 10 percent equity position in PharmaCann.

As quoted in the press release:

PharmaCann currently operates with existing licenses to import, export and wholesale medical cannabis issued by the Australian Government Department of Health. Namaste’s investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license. The Australian market represents a major component of Namaste’s current revenue, which is derived in hardware sales, and remains a primary focus of Namaste’s strategic initiatives as it looks to target the Australian medical cannabis industry. Namaste believes PharmaCann’s import, export and wholesale licenses bring immediate value to the Company and believes that  PharmaCann has the ability to obtain a cultivation license which will further enhance Namaste’s ability to penetrate global markets. In addition to Namaste’s strategic investment in PharmaCann, the Terms Sheet outlines additional business ventures between both parties as outlined below.

Namaste remains committed to focusing on opportunities and collaborations with PharmaCann in the Australian market, as it represents an important part of the Company’s growth strategy moving forward. As the Canadian market progresses closer towards full legalization, Namaste is of the opinion that additional markets, such as Australia, will provide Namaste with a more diverse market presence by allowing the Company to continue leveraging its global database of cannabis users. This strategy represents an opportunity for Namaste to expand its global ecommerce platform into other progressive markets, as it looks to replicate the success it has achieved in the Canadian market.

Click here to read the full press release.


American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less